• Tamoxifen in Gut Inflammation and CreER Models

  2026-08-12

  Tamoxifen is more than a selective estrogen receptor modulator: in inducible mouse genetics, it can shape how neuroimmune and epithelial phenotypes are interpreted. This guide connects Tamoxifen CreER-mediated gene knockout design with a recent intestinal inflammation study and practical assay controls.

• JXY Reprograms Macrophages in Colitis-Associated CRC

  2026-08-12

  The reference study shows that Jiedu Xiaozheng Yin limits colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1-like phenotype through TLR4-associated signaling. Its combination of orthotopic disease modeling, macrophage phenotyping, phagocytosis assays, and pathway antagonism provides a useful framework for studying how complex interventions reshape the tumor immune microenvironment.

• O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia

  2026-08-11

  The 2026 reference study identifies an O-GlcNAc–HUWE1–TfR1 pathway that connects trophoblast ferroptosis with defective syncytialization in preeclampsia. Its evidence supports a mechanistic model in which increased O-GlcNAc modification stabilizes HUWE1, promotes TfR1 ubiquitination and degradation, limits iron uptake, and improves placental and pregnancy-related outcomes in experimental models.

• Cycloastragenol Limits Glucocorticoid Bone Loss

  2026-08-10

  This in vivo study shows that cycloastragenol reduced femoral-head necrosis and trabecular bone loss in a methylprednisolone-induced rat model of glucocorticoid-induced osteonecrosis. Its central contribution is to connect structural and vascular protection with suppression of osteoclast-associated signaling, supporting further investigation of osteoclast control as a hip-preservation strategy.

• Roxadustat, HIF–GATA1 Signaling, and Erythroleukemia

  2026-08-09

  The reference study shows that roxadustat promotes erythroid differentiation in HEL and K562 erythroleukemia cells through an HIF-α/GATA1 regulatory axis, with HIF-2α acting as the principal mediator of the drug response. Its combination results further indicate cell-model-dependent synergy with ruxolitinib or imatinib, providing a mechanistic framework for studying hypoxia, differentiation, and kinase signaling in myeloid malignancy models.

• Cepharanthine in Endometriosis: Organoid and In Vivo Evidenc

  2026-08-08

  A 2026 study evaluated Cepharanthine across immortalized stromal cells, patient-derived endometriotic cells, endometrial organoids, and a murine lesion model. The findings connect reduced lesion growth with G0/G1 arrest, DNA damage, impaired DNA repair, and mitochondrial apoptosis, while also illustrating the value of organoids for preclinical endometriosis research.

• ABT-263 (Navitoclax) for Apoptosis Workflows

  2026-08-07

  ABT-263 (Navitoclax) provides a practical way to test Bcl-2 family dependence, mitochondrial priming, and caspase-linked cell death in cancer models. This guide combines assay-ready handling advice with a metabolism-informed workflow inspired by hydride transfer complex research.

• Faropenem Sodium: Mechanistic Insights for Translational Res

  2026-08-07

  This article explores Faropenem sodium’s unique mechanistic profile as a penem antibiotic, bridging transporter biology, broad-spectrum antimicrobial action, and translational research design. By integrating molecular insights, comparative efficacy, and practical workflow guidance, it delivers strategic recommendations for researchers tackling antibiotic resistance and infection modeling.

• Mildronate-Derived Lipidoids Minimize mRNA Vaccine Inflammat

  2026-08-06

  A recent ACS Nano study demonstrates that mildronate-derived cationic lipidoids allow for efficient mRNA vaccine delivery with significantly reduced inflammatory side effects compared to conventional lipid nanoparticles. This innovation addresses a critical barrier in the clinical translation of mRNA vaccines, offering a path toward safer immunogen research and therapeutic applications.

• RIPA Lysis Buffer (Strong): Unraveling Protein Extraction in

  2026-08-06

  Explore how RIPA Lysis Buffer (Strong) advances protein extraction from animal tissues for inflammation and cardiac research. This in-depth article highlights unique mechanistic insights and practical guidance, distinguishing itself from prior content.

• Vincristine Sulfate: Optimizing Microtubule Disruption in Ca

  2026-08-05

  Vincristine sulfate stands as a benchmark microtubule disrupter, empowering cancer researchers with robust, reproducible protocols for both in vitro and in vivo applications. This article distills best practices, advanced troubleshooting, and the latest translational insights—positioning APExBIO’s Vincristine sulfate as a gold-standard reagent for oncology innovation.

• Nanococktail Restores Bone-Immune Balance in Senile Osteopor

  2026-08-05

  This study introduces a nanococktail therapy that targets both circadian rhythm regulation and efferocytosis in bone marrow-derived macrophages to treat senile osteoporosis. The approach leverages melatonin-loaded, bone-targeting nanovesicles to simultaneously inhibit bone resorption and promote bone formation, addressing key pathophysiological mechanisms overlooked by conventional treatments.

• Dantrolene Sodium Salt: Precision Modulation in CRISPR and C

  2026-08-04

  Dantrolene sodium salt empowers researchers to fine-tune intracellular calcium release and DNA repair pathway outcomes, unlocking new precision in CRISPR genome editing and disease modeling. Its unique calmodulin-dependent RyR antagonism, high purity, and proven efficacy across ischemia and neurodegeneration models set it apart as an advanced tool for both troubleshooting and innovation.

• Practical Guide: Caspase-3 Colorimetric Assay Kit (SKU K2008

  2026-08-04

  The Caspase-3 Colorimetric Assay Kit provides a sensitive, DEVD-dependent workflow for detecting caspase-3 activity—a critical marker in apoptosis and neurodegenerative research. This tool is best suited for quantifying cysteine-dependent aspartate-directed protease activity in cell lysates or tissue extracts, but is not recommended for direct use in live-cell imaging or high-throughput screening without protocol adaptation.

• Mithramycin A: Precision Modulation of Sp1 and c-myc in Leuk

  2026-08-03

  Explore how Mithramycin A, an anticancer antibiotic, enables precise modulation of Sp1 and c-myc pathways in leukemia research. This article uniquely dissects the compound’s dual impact on gene expression and cardiac signaling, offering advanced insights beyond protocol troubleshooting.

448 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page